Evidence map›Paper›PMID 39604409›Full record

ArticleNature communications2024

Neonatal immunity associated with heterologous HIV-1 neutralizing antibody induction in SHIV-infected Rhesus Macaques.

Sommer Holmes, Hui Li, Xiaoying Shen, Mitchell Martin, Ryan Tuck, Yue Chen, Elena E Giorgi, Hélène Fradin Kirshner, Madison Berry, Elizabeth Van Italie and 25 more

Abstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors.

Sommer Holmes *Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.ORCID 0009-0009-8205-2616
Hui Li *Departments of Medicine and Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Xiaoying Shen *Department of Surgery, Duke University School of Medicine, Durham, NC, USA.ORCID 0000-0002-8387-3952
Mitchell Martin *Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Ryan Tuck *Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.ORCID 0000-0003-0697-0924
Yue Chen *Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Elena E GiorgiFred Hutchinson Cancer Center, Seattle, WA, USA.
Hélène Fradin KirshnerDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Madison BerryDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Elizabeth Van ItalieDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Sravani VenkatayogiDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Joshua S Martin BeemDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Robert J EdwardsDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.ORCID 0000-0003-4446-1194
Katayoun MansouriDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Ajay SinghDepartments of Medicine and Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Cindy KuykendallDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Thaddeus GurleyDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
M Anthony MoodyDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Nicole DeNayerDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Todd DemarcoDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Thomas N DennyDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Yunfei WangDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.ORCID 0000-0002-3205-6338
Tyler D EvangelousDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
John T ClintonDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Bhavna HoraDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
Kshitij WaghLos Alamos National Laboratory, Los Alamos, NM, USA.ORCID 0000-0001-7552-6582
Michael S SeamanBeth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Kevin O SaundersDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.ORCID 0000-0001-7399-7954
Nicholas SolomotisBIOQUAL Inc., Rockville, MD, USA.
Johnathan MisamoreBIOQUAL Inc., Rockville, MD, USA.
Mark G LewisBIOQUAL Inc., Rockville, MD, USA.ORCID 0000-0001-7852-0135
Kevin WieheDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.
David C MontefioriDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA.ORCID 0000-0003-0856-6319
George M ShawDepartments of Medicine and Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Wilton B WilliamsDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, USA. wilton.williams@duke.edu.ORCID 0000-0002-2970-7259

Funding

Social and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI Amy Lynn Corneli · 2005 to 2026
$50.5M
Virus and Antibody Gene Sequencing CoreP01AI131251 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Kevin Wiehe · 2017 to 2026
$40.7M
Optimizing glycan shield coverage, germline B cell receptor binding and epitope diversity of V2-apex targeted HIV-1 Env immunogensR37AI150590 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Beatrice H Hahn · 2019 to 2026
$6.9M
Neonatal Immunity to novel TF SHIVsR01AI140897 · NIAID · DUKE UNIVERSITY · PI WILLIAMS, WILTON B · 2018 to 2022
$4.4M
Reverse Vaccinology in SHIV Infected Macaques as a Molecular Guide for HIV-1 Vaccine DesignR01AI160607 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI SHAW, GEORGE M · 2021 to 2024
$3.2M
Neonatal Immunity to novel TF SHIVsR37AI140897 · NIAID · DUKE UNIVERSITY · PI Wilton B Williams · 2024 to 2026
$2.4M
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (Division of Intramural Research of the NIAID) AI140897Division of Intramural Research, National Institute of Allergy and Infectious Diseases (Division of Intramural Research of the NIAID) AI160607NIAID NIH HHS HHSN272201800004CNIAID NIH HHS P01 AI131251NIAID NIH HHS P30 AI064518NIAID NIH HHS R01 AI140897NIAID NIH HHS R01 AI160607NIAID NIH HHS R37 AI140897NIAID NIH HHS R37 AI150590
6 · The paper itself

Abstract

The details of the pediatric immune system that supports induction of antibodies capable of neutralizing geographically-diverse or heterologous HIV-1 is currently unclear. Here we explore the pediatric immune environment in neonatal macaque undergoing Simian-HIV infection. Simian-HIV infection of 11 pairs of therapy-naive dams and infant rhesus macaques for 24 months results in heterologous HIV-1 neutralizing antibodies in 64% of young macaques compared to 18% of adult macaques. Heterologous HIV-1 neutralizing antibodies emerge by 12 months post-infection in young macaques, in association with lower expression of immunosuppressive genes, fewer germinal center CD4 + T regulatory cells, and a lower ratio of CD4 + T follicular regulatory to helper cells. Antibodies from peripheral blood B cells in two young macaques following SHIV infection neutralize 13% of 119 heterologous HIV-1 strains and map to regions of canonical broadly neutralizing antibody epitopes on the envelope surface protein. Here we show that pediatric immunity to SHIV infection in a macaque model may inform vaccine strategies to induce effective HIV-1 neutralizing antibodies in infants and children prior to viral exposure.

Indexed as

Animals, NewbornAntibodies, NeutralizingHIV-1HIV AntibodiesMacaca mulattaSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusAnimalsB-LymphocytesDisease Models, AnimalEpitopesFemaleGerminal CenterHIV InfectionsHumansMaleAntibodies, NeutralizingEpitopesHIV Antibodies

Identifiers

PMID39604409
PMCPMC11603298

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.